Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

The role of non-invasive biomarker M2BPGi in managing liver disease in Vietnamese patients

Thuy Thi Thu Pham

Chronic liver disease has a high global burden and death toll. Early diagnosis is important to halt disease progression to cirrhosis, hepatocellular carcinoma, and eventually death. At present, there are many methods used for liver disease assessment, such as liver biopsy, elastography, serum biomarkers, and surrogate markers. However, shortcomings of these methods include invasiveness, costly equipment, requirements for skilled technicians, long turnaround and waiting times, which limit their usefulness, particularly in developing countries in the world that lack resources and skilled technicians. Vietnam is a developing country with a high burden of hepatitis B and C, and liver disease-related mortality is expected to increase in 2025. A recent study in Vietnam found that the Mac-2 binding protein glycosylation isomer (M2BPGi) levels are correlated with elastography used for liver fibrosis staging. In this review, we examined the challenges and prevalence of liver disease in Vietnam. We also reviewed the literature on the use of M2BPGi in liver disease in other countries and discuss how this marker can be used to improve the detection and management of liver disease as well as the challenges and problems faced.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado.